Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) PT at $23.00

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been given an average recommendation of “Reduce” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $23.00.

Several equities analysts have recently issued reports on IART shares. Citigroup boosted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company.

Integra LifeSciences Stock Up 4.4 %

Shares of Integra LifeSciences stock opened at $22.05 on Thursday. The business has a fifty day simple moving average of $23.68 and a 200 day simple moving average of $21.81. The stock has a market cap of $1.70 billion, a PE ratio of -244.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $44.91.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in IART. Principal Financial Group Inc. lifted its holdings in shares of Integra LifeSciences by 18.7% in the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock valued at $7,294,000 after purchasing an additional 63,266 shares in the last quarter. Versor Investments LP bought a new stake in Integra LifeSciences in the 3rd quarter valued at approximately $612,000. BNP Paribas Financial Markets boosted its position in Integra LifeSciences by 824.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock worth $2,031,000 after acquiring an additional 99,685 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Integra LifeSciences during the 3rd quarter worth approximately $960,000. Finally, State of Alaska Department of Revenue grew its stake in shares of Integra LifeSciences by 144.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock worth $2,393,000 after acquiring an additional 77,825 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.